LT4920B - Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui - Google Patents

Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui Download PDF

Info

Publication number
LT4920B
LT4920B LT2001045A LT2001045A LT4920B LT 4920 B LT4920 B LT 4920B LT 2001045 A LT2001045 A LT 2001045A LT 2001045 A LT2001045 A LT 2001045A LT 4920 B LT4920 B LT 4920B
Authority
LT
Lithuania
Prior art keywords
agent
composition
antibody
cell
factor viii
Prior art date
Application number
LT2001045A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2001045A (en
Inventor
Jiahua Qian
Leon W. Hoyer
Mary Collins
Gary S. Gray
Original Assignee
Genetics Institute,Inc.
American Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute,Inc., American Red Cross filed Critical Genetics Institute,Inc.
Publication of LT2001045A publication Critical patent/LT2001045A/xx
Publication of LT4920B publication Critical patent/LT4920B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LT2001045A 1998-09-21 2001-04-20 Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui LT4920B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21

Publications (2)

Publication Number Publication Date
LT2001045A LT2001045A (en) 2002-01-25
LT4920B true LT4920B (lt) 2002-06-25

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2001045A LT4920B (lt) 1998-09-21 2001-04-20 Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui

Country Status (21)

Country Link
EP (1) EP1115423A1 (zh)
JP (1) JP2002526455A (zh)
KR (1) KR20010085830A (zh)
CN (1) CN1331602A (zh)
AU (1) AU761206B2 (zh)
BR (1) BR9913991A (zh)
CA (1) CA2343916A1 (zh)
CZ (1) CZ20011021A3 (zh)
EA (1) EA005236B1 (zh)
HK (1) HK1039059A1 (zh)
HU (1) HUP0103960A3 (zh)
IL (1) IL142069A0 (zh)
LT (1) LT4920B (zh)
LV (1) LV12768B (zh)
MX (1) MXPA01002898A (zh)
NO (1) NO20011412L (zh)
NZ (1) NZ511034A (zh)
PL (1) PL346796A1 (zh)
SI (1) SI20626A (zh)
WO (1) WO2000016801A1 (zh)
ZA (1) ZA200103156B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DE60118362T2 (de) * 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
US7040139B2 (en) * 2003-06-10 2006-05-09 Smiths Detection Inc. Sensor arrangement
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
WO1993000431A1 (en) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5583209A (en) 1992-04-07 1996-12-10 Emory University Hybrid human/porcine factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5679639A (en) 1991-11-18 1997-10-21 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5707832A (en) 1990-02-05 1998-01-13 Tm Innovation Process for the preparation of human factor VIII and analogs of factor VIII
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US8701299B2 (en) 2009-11-06 2014-04-22 Hexagon Metrology Ab CMM with modular functionality

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
CN1261285A (zh) * 1997-06-20 2000-07-26 拜奥根有限公司 治疗性蛋白抑制剂综合症的cd154阻断治疗

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5707832A (en) 1990-02-05 1998-01-13 Tm Innovation Process for the preparation of human factor VIII and analogs of factor VIII
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
WO1993000431A1 (en) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5679639A (en) 1991-11-18 1997-10-21 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5583209A (en) 1992-04-07 1996-12-10 Emory University Hybrid human/porcine factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US8701299B2 (en) 2009-11-06 2014-04-22 Hexagon Metrology Ab CMM with modular functionality

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
BLUESTONE JA: "New perspectives of CD28-B7-mediated T cell costimulation", IMMUNITY., 1995, pages 555
C. D. GIMMI ET AL.: "B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2", PROC NATL ACAD SCI USA., 1991, pages 6575 - 6579
C. H. JUNE ET AL.: "Role of the CD28 receptor in T cell activation", IMMUNOL. TODAY., 1990, pages 211 - 216, XP026942223, DOI: doi:10.1016/0167-5699(90)90085-N
CONNELLY S, MOUNT J, MAUSER A, ET AL.: "Complete short-term correction of canine hemophilia A by in vivo gene therapy", BLOOD, 1996, pages 3846, XP002926495
D. J. LENSCHOW ET AL.: "CD28/B7 system of T cell costimulation", ANNU REV IMMUNOL., 1996, pages 233, XP000916005, DOI: doi:10.1146/annurev.immunol.14.1.233
F. HARDING ET AL.: "CD28-mediated signaling costimulates murine T cells and prevents the induction of anergy in T cell clones", NATURE, 1992, pages 607 - 609
G. J. FREEMAN ET AL.: "B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells", THE JOURNAL OF IMMUNOLOGY, 1991, pages 2714
G. J. FREEMAN ET AL.: "Cloning of B7-2: CTLA-4 counter-receptor that costimulates human T cell proliferation", SCIENCE, 1993, pages 909, XP002069402, DOI: doi:10.1126/science.7694363
G. J. FREEMAN ET AL.: "Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7", J EXP MED., 1991, pages 625, XP000608218, DOI: doi:10.1084/jem.174.3.625
H. REISER ET AL.: "Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex", PROC NATL ACAD SCI USA., 1992, pages 271 - 275
ISSELBACHER ET AL.: "Harrisons Principles of Internal Medicine, 13th Ed."
J. F. BRUNET ET AL.: "A new member of the immunoglobulin superfamily: CTLA-4", NATURE, 1987, pages 267 - 270, XP002915323, DOI: doi:10.1038/328267a0
J. W. YOUNG ET AL.: "The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro", J CLIN INVEST., 1992, pages 229 - 237
JENKINS MK, ASHWELL JD, SCHWARTZ RH: "Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells", J IMMUNOL., 1988, pages 3324 - 3330
L. KOULOVA: "The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells", J EXP MED., 1991, pages 759 - 762
LASALLE JM, OTA K, HAFLER DA: "Presentation of autoantigen by human T cells", J IMMUNOL., 1991, pages 774 - 780
M. JENKINS, R. SCHWARTZ: "Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo", J EXP MED., 1987, pages 302 - 319, XP000877390, DOI: doi:10.1084/jem.165.2.302
M. L. DUSTIN ET AL.: "Correlation of CD2 binding and functional properties of multimeric and monomeric lymphocyte function-associated antigen 3.", J. EXP. MED, 1989, pages 503
MUELLER DL, JENKINS MK, CHIODETTI L, SCHWARTZ: "An intracellular calcium increase and protein kinase C activation fail to initiate T cell proliferation in the absence of a costimulatory signal", J IMMUNOL., 1990, pages 3701 - 3709
P. S. LINSLEY ET AT.: "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation", J EXP MED., 1991, pages 721 - 730, XP000611265, DOI: doi:10.1084/jem.173.3.721
R. J. ARMITAGE ET AL.: "Molecular and biological characterization of a murine ligand for CD40", NATURE, 1992, pages 80 - 82, XP002024662, DOI: doi:10.1038/357080a0
VAN SEVENTER GA ET AL.: "The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells", J IMMUNOL., 1990, pages 4579 - 4586
Y. LIU ET AL.: "Heat-stable antigen is a constimulatory molecule for CD4 T cell growth", J. EXP. MED., 1992, pages 437 - 445

Also Published As

Publication number Publication date
EA200100385A1 (ru) 2001-10-22
LV12768A (en) 2001-12-20
NO20011412L (no) 2001-05-16
HK1039059A1 (zh) 2002-04-12
LV12768B (lv) 2002-06-20
CN1331602A (zh) 2002-01-16
ZA200103156B (en) 2002-07-18
CZ20011021A3 (cs) 2001-10-17
EP1115423A1 (en) 2001-07-18
HUP0103960A2 (hu) 2002-02-28
AU761206B2 (en) 2003-05-29
LT2001045A (en) 2002-01-25
NO20011412D0 (no) 2001-03-20
AU6057899A (en) 2000-04-10
IL142069A0 (en) 2002-03-10
EA005236B1 (ru) 2004-12-30
KR20010085830A (ko) 2001-09-07
PL346796A1 (en) 2002-02-25
SI20626A (sl) 2002-02-28
WO2000016801A1 (en) 2000-03-30
BR9913991A (pt) 2001-07-03
HUP0103960A3 (en) 2003-09-29
JP2002526455A (ja) 2002-08-20
NZ511034A (en) 2004-03-26
WO2000016801A9 (en) 2000-10-26
MXPA01002898A (es) 2002-06-04
CA2343916A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
Qian et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A
Lollar Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX
Thien et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches
JP5580535B2 (ja) 癌転移および癌転移に関連する骨量減少を予防および処置するための方法
AU709711B2 (en) Methods for modulating T cell unresponsiveness
US11547741B2 (en) Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
Qian et al. Role of CD154 in the secondary immune response: the reduction of pre‐existing splenic germinal centers and anti‐factor VIII inhibitor titer
US20120269806A1 (en) Methods of inducing tolerance
Hünig Manipulation of regulatory T‐cell number and function with CD28‐specific monoclonal antibodies
US20080095774A1 (en) Agents and Methods for Specifically Blocking CD28-Mediated Signaling
Saenko et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action
US20210340214A1 (en) Cd80 extracellular domain fc fusion protein dosing regimens
BG64436B1 (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
AU761206B2 (en) Methods of downmodulating the immune response to therapeutic proteins
US20210355231A1 (en) Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
Fijnvandraat et al. Immunobiology of inhibitor development in hemophilia A
US20030161827A1 (en) Therapies that improve graft survival
US20230023174A1 (en) Cd80 extracellular domain fc fusion protein regimens
US20020071839A1 (en) Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
Bril Factor VIII inhibitors in mild haemophilia A
KR20230038658A (ko) Adamts13 단백질 변형체 및 그것의 용도
Dobbins Signaling of the T Cell Costimulatory Receptor CD28: Regulation and Initiation
Miao et al. Immunomodulation of transgene responses following naked DNA transfer
Erkan et al. What are the Potential Future Treatments in Antiphospholipid Syndrome?
AU3437902A (en) Methods for modulating T cell unresponsiveness

Legal Events

Date Code Title Description
PD9A Change of patent owner

Owner name: AMERICAN RED CROSS, US

Free format text: FORMEROWNER: GENETICS INSTITUTE, LLC, US

Effective date: 20031223

MM9A Lapsed patents

Effective date: 20050921